Stock info Biogen | Filter  Basic-Info

Stock: Biogen (US Tech), ISIN: US09062X1037

Last Price 220.75 Max Price 318.06
Min Price 216.99 1 Year return -7.99
Sector Health Care Subsector Biotechnology
Annual report 2020

Biogen Inc., a global biotechnology leader with products and capabilities in oncology, neurology and immunology, is committed to transforming scientific discovery into advances in healthcare. Biogen's core capabilities include drug discovery, research, development, biomanufacturing, and a global commercial infrastructure. Biogen currently employs approximately 3,900 people worldwide. Biogen’s stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US09062X1037/ Symbol: BIIB).

Loading...

Contact info:Street: 133 Boston Post RoadZip Code: MA 02493City: WestonCountry: USAPhone: (781) 4642000Email: info@biogenidec.comWebsite: www.biogen.comCEO: GEORGE A. SCANGOSCFO: Paul J. Clancy

Sector Review Biogen

Loading...
Year Turnover Total sector Market share
2019 14,378 141,925 10.13 %
2020 13,445 170,231 7.90 %
2021 10,982 252,886 4.34 %
2022 10,173 238,500 4.27 %
2023 0 0 0.00 %

Advice Biogen

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
October 08, 2021 Jefferies & Co. Biogen Hold 400.00 33.92 %
November 10, 2020 DZ Bank Biogen Buy 265.00 24.12 %
November 06, 2020 KBC Securities Biogen Hold 150.00 -34.05 %
November 05, 2020 ABN AMRO Biogen Hold 354.00 43.20 %
July 27, 2020 Morgan Stanley Biogen Buy 357.00 43.68 %
July 23, 2020 RBC Capital Markets Biogen Hold 284.00 29.20 %
April 24, 2020 Canacord Adams Biogen Buy 350.00 42.55 %
April 23, 2020 Citigroup Biogen Sell 240.00 16.22 %
February 07, 2020 Morgan Stanley Biogen Hold 320.00 16.44 %
February 07, 2020 BMO Capital Markets Biogen Hold 317.00 36.57 %
February 07, 2020 ABN AMRO Biogen Buy 421.00 36.49 %
February 07, 2020 Wells Fargo Biogen Hold 311.00 35.34 %
February 07, 2020 Citigroup Biogen Hold 365.00 26.74 %
February 06, 2020 Cowen and Company Biogen Buy 355.00 43.36 %
January 31, 2020 Jefferies & Co. Biogen Hold 320.00 16.29 %
December 03, 2019 Robert W. Baird Biogen Sell
October 24, 2019 ABN AMRO Biogen Buy
October 23, 2019 Jefferies & Co. Biogen Hold 310.00 13.25 %
October 23, 2019 Oppenheimer & Co Biogen Buy 334.00 39.80 %
October 23, 2019 Piper Jaffray Biogen Hold 305.00 34.07 %
October 16, 2019 Oppenheimer & Co Biogen Buy 280.00 -4.09 %
July 24, 2019 Citigroup Biogen Hold 255.00 -10.84 %
July 24, 2019 RBC Capital Markets Biogen Hold 242.00 -16.80 %
July 24, 2019 Jefferies & Co. Biogen Hold 270.00 -4.69 %
June 28, 2019 Piper Jaffray Biogen Hold 250.00 -5.05 %
May 24, 2019 Citigroup Biogen Hold 245.00 -24.27 %
May 21, 2019 Credit Suisse Biogen Sell 198.00 -1.56 %
March 23, 2019 UBS Biogen Hold 242.00 16.91 %
March 23, 2019 Morgan Stanley Biogen Hold 210.00 -32.75 %
March 23, 2019 BMO Capital Markets Biogen Hold 250.00 -11.51 %
March 23, 2019 Jefferies & Co. Biogen Hold 250.00 -11.51 %
February 13, 2019 RBC Capital Markets Biogen Hold 318.00 -6.86 %
January 31, 2019 Morgan Stanley Biogen Hold 401.00 98.12 %
January 31, 2019 Leerink Swann & Company Biogen Buy 341.00 41.03 %
January 31, 2019 RBC Capital Markets Biogen Hold 337.00 97.77 %
January 31, 2019 Oppenheimer & Co Biogen Buy 380.00 98.02 %
November 27, 2018 RBC Capital Markets Biogen Hold 338.00 10.47 %
October 24, 2018 Morgan Stanley Biogen Hold 394.00 23.53 %
October 19, 2018 Sanford C. Bernstein & Co Biogen Hold 341.00 41.03 %
August 07, 2018 Stifel Biogen Buy



News Biogen

Analysts expect over 2021 decreasing revenue Biogen

Tomorrow the American Biogen will report its past quarters results. Over the current book year the total revenu from the company based in Cambridge will be 9.88 billion USD (consensus estimates). This is hugely lower than 2021's revenue of 10.98 billion USD....

Analysts expect over 2021 decreasing revenue Biogen

Tomorrow Biogen will publish its past quarters results. For this year Biogen 's (located in Cambridge) revenue will be around 10.87 billion USD. This is according to the average of the analysts' estimates. This is hugely lower than 2021's revenue of 13.44 billion...

Analysts expect over 2021 decreasing revenue Biogen

Tomorrow the American Biogen will report its past quarters results. For this year Biogen 's (located in Cambridge) revenue will be around 10.77 billion USD. This is according to the average of the analysts' estimates. This is rather significant lower than 2021's...

Analysts expect sales decline Biogen

Tomorrow Biogen will publish its past quarters results. Over the current book year the total revenu from the company based in Cambridge will be 10.64 billion USD (consensus estimates). This is rather significant lower than 2021's revenue of 13.44 billion USD....

Analysts foresee less revenue Biogen

Tomorrow Biogen will publish its past quarters results. Over the current book year the company from Cambridge could achieve a revenue around 10.57 billion USD (consensus estimates). This is quite lower than 2020's revenue of 13.44 billion USD. Historical revenues...

Annual reports Biogen

2017 2018 2019 2020 2021

Profile Biogen

Biogen

(US09062X1037)/ BIIB

Biogen's headquarter is based in Weston. Biogen is mostly active in the biotech sector. Biogen is being led by CEO GEORGE A. SCANGOS. Paul J. Clancy runs the company as a CFO. The global biotech companies gained around 59 percent over the period 2006-2016. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year was a profitable year for Biogen investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 4 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 153 percent. Biogen's revenues between 2011 and 2015 were quite unstable and moved between 5,52 billion dollars and 10,76 billion dollars. Biogen's net incomes between 2011 and 2015 were very volatile and moved between 1,27 billion dollars and 3,61 billion dollars.

The American company didn't pay out any dividends (in the past 5 years).

At the end of 2015 around 7550 thousand people were employed at Biogen.

Biogen financed with a quite low debt position

Last year the balance sheet of the American company was worth 19,5 billion dollars. The total debt was around 10,13 billion dollars. This is 51,95 percent of the total balance sheet. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 22. So the stock' value was 22 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 65,16 billion dollars. At the end of 2015 the American company had around 218,6 million stocks listed.

All the annual reports of Biogen are available here. More information about Biogen can be found it's website. .


Results Biogen

Results
2015
2016
2017
2018
2019
2020
Revenue
10,764
11,449
12,274
13,453
14,378
13,445
Costs
7,217
7,746
9,735
9,022
8,489
9,444
Profit
3,547
3,703
2,539
4,431
5,889
4,001
Margin of profit
32.95
32.34
20.69
32.93
40.96
29.76
ROI
37.84
30.50
20.13
33.98
44.13
37.39

Balance Biogen

Balance
2015
2016
2017
2018
2019
2020
Equity
9,373
12,140
12,613
13,040
13,343
10,700
Debt
10,132
10,737
11,040
12,249
13,891
13,919
Total assets
19,505
22,877
23,653
25,289
27,234
24,619
Solvency
48.05
53.07
53.33
51.56
48.99
43.46
Cash
3,429
4,895
3,689
3,538
4,476
2,610
Cashflow
3,919
4,587
4,551
6,188
7,079
4,230
Employees
0
0
0
0
0
Revenue per employee
0.0
0.0
0.0
0.0
0.0
Cashflow / Debt
0.39
0.43
0.41
0.51
0.51
0.30

Details Biogen

Details
2016
2017
2018
2019
2020
Price
282.18
261.21
318.57
300.92
296.73
Eps
16.92
11.92
21.58
31.42
24.80
Price/earnings-ratio
16.68
21.91
14.76
9.58
8.90
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
56.23
59.63
66.12
76.60
70.21
Market to book
0.20
0.23
0.21
0.25
0.32
Cashflow per stock
21.25
21.52
31.38
40.63
27.75
Stocks
216
212
197
174
152
Market Cap
60.922.66
55.245.92
62.822.00
52.420.26
33.642.30

Dividend Biogen


Price info Biogen

Date
Price
22 Mar 2024
220.75
18 Mar 2024
219.31
15 Mar 2024
219.62
12 Mar 2024
230.07
11 Mar 2024
223.24
09 Mar 2024
223.24
07 Mar 2024
217.56
01 Mar 2024
216.99
29 Feb 2024
221.74
27 Feb 2024
223.71
22 Feb 2024
221.11
21 Feb 2024
219.21
20 Feb 2024
219.08
15 Feb 2024
220.74
14 Feb 2024
226.65
13 Feb 2024
244.74
09 Feb 2024
240.30
08 Feb 2024
240.54
07 Feb 2024
245.55
06 Feb 2024
241.84
05 Feb 2024
243.72
01 Feb 2024
246.66
31 Jan 2024
247.08
30 Jan 2024
247.52
27 Jan 2024
244.82
25 Jan 2024
247.16
24 Jan 2024
251.68
23 Jan 2024
248.30
16 Jan 2024
248.12
11 Jan 2024
254.23